The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma

• Published in: Journal of experimental & clinical cancer research 2009-06, Vol.28 (1), p.91-91
• Main Authors: Cheng, Xiao-Dong, Lu, Wei-Guo, Ye, Feng, Wan, Xiao-Yun, Xie, Xing
• Format: Article
• Language: English
• Subjects: Adjuvant treatment; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer; Cervical cancer; DNA-Binding Proteins - genetics; DNA-Binding Proteins - metabolism; Drug therapy; Female; Genetic aspects; Genotype; Health aspects; Humans; Immunoenzyme Techniques; Neoadjuvant Therapy; Polymorphism, Single Nucleotide - genetics; Prognosis; Single nucleotide polymorphisms; Uterine Cervical Neoplasms - drug therapy; Uterine Cervical Neoplasms - genetics; X-ray Repair Cross Complementing Protein 1
• ISSN: 0392-9078; 1756-9966; 1756-9966
• DOI: 10.1186/1756-9966-28-91

Platinum-based neoadjuvant chemotherapy (NAC) is new therapeutic strategy for locally advanced cervical carcinoma, but the variables used to predict NAC response are still infrequently reported. The aim of our study was to investigate the association between XRCC1 gene single nucleotide polymorphisms (SNPs) and NAC response. Seventy patients with locally advanced cervical carcinoma who underwent NAC were collected. SNPs of XRCC1 (at codon 194 and 399) and XRCC1 protein expression were detected. The association of XRCC1 gene SNPs and protein expression with NAC response were analyzed. Response to NAC was not statistically significant in three genotypes, Arg/Arg, Arg/Trp, Trp/Trp of XRCC1 at codon 194(X(2) = 1.243, P = 0.07), while responses were significantly different in genotypes Arg/Arg, Arg/Gln, Gln/Gln of XRCC1 at codon 399 (X(2) = 2.283, P = 0.020). The risk of failure to chemotherapy in the patients with a Gln allele(Arg/Gln+Gln/Gln) was significantly greater than that with Arg/Arg(OR = 3.254, 95%CI 1.708 approximately 14.951). The expression level of XRCC1 protein was significantly associated with response to NAC. Moreover, the genotype with the Gln allele(Arg/Gln+Gln/Gln) at codon 399, but not codon at 194, presented a significantly higher level of XRCC1 protein expression than that with Arg/Arg genotype (F = 2.699, p = 0.009). SNP of XRCC1 gene at codon 399 influences the response of cervical carcinoma to platinum-based NAC. This is probably due to changes in expression of XRCC1 protein, affecting response to chemotherapy.